Skip to main content
SpringerLink
Log in

Management of Diabetes Mellitus

  • Chapter
  • First Online:
Diabetes Mellitus in 21st Century

Abstract

DM is acknowledged as a serious medical problem since the last two centuries, but still represents a major medical challenge. Early detection of DM/prediabetes condition offers an opportunity to provide better management and to avert consequences of DM. Modern treatments and discovery of new medicines could be helpful to stop the devastating condition DM and continue to improve outcomes. But non-pharmacological approaches are essential and considered as a key strategy to remain healthy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aggarwal A. Saroglitazar: India’s answer to diabetic dyslipidemia. Int J Pharmacol Clin Sci. 2014;3:7–14.

    Google Scholar 

  • Alwan AAS. Management of diabetes mellitus standards of care and clinical practice guidelines. Egypt: World Health Organization; 1994.

    Google Scholar 

  • Azad SS, Isenovic ER, Yaturu S, Mousa SA. Insulin therapy for diabetes. In: Mauso K, editor. Type 2 Diabetes. Croatia: Intech; 2013.

    Google Scholar 

  • Babu S. Vildagliptin – a new prospect in management of type 2 diabetes. Indian J Clin Pract. 2012;22:377–85.

    Google Scholar 

  • Badyal DK, Kaur J. Sitagliptin: a new class of oral drug for type 2 diabetes. JK Sci. 2008;10:97–8.

    Google Scholar 

  • Bailey CJ, Day C. Metformin: its botanical background. Pract Diab Int. 2004;21:115–7.

    Article  Google Scholar 

  • Bailey CJ. Biguanides and NIDDM. Diabetes Care. 1992;15:755–72.

    Article  CAS  PubMed  Google Scholar 

  • Bibu MG, Manoj P, Bhuvaneswari S. Non-Pharmacological management of type 2 DM; Where do we stand? Int J Clin Cases Invest. 2011;2:27–34.

    Google Scholar 

  • Charbonnel B. PPAR-α and PPAR-γ agonists for type 2 diabetes. Lancet. 2009;374:96–8.

    Article  PubMed  Google Scholar 

  • Cheng AYY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. Can Med Assoc J. 2005;172:213–26.

    Article  Google Scholar 

  • Chiarelli F, Marzio DD. Peroxisome proliferator-activated receptor-γ agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag. 2008;4:297–304.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Cox ME, Rowell J, Corsino L, Green JB. Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug Healthc Pat Saf. 2010;2:7–19.

    CAS  Google Scholar 

  • Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab. 2013;24:85–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Das S, Panda JK. Glitazones are superior oral antidiabetics. In: Adik-Pathak L, editor. Post graduate medicine, vol. 18. Mumbai: Association of Physician in India; 2004, p. 327–29.

    Google Scholar 

  • Davis SN. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006.

    Google Scholar 

  • Day C. Amylin analogue as an antidiabetic agent. Br J Diab Vasc Dis. 2005;5:151–4.

    Article  CAS  Google Scholar 

  • Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13:7–18.

    Article  CAS  PubMed  Google Scholar 

  • DiStefano JK, Watanabe RM. Pharmacogenetics of anti-diabetes drugs. Pharmaceuticals. 2010;3:2610–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Donnelly R. Canagliflozin: SGLT2 inhibitor for treating type 2 diabetes. Fut Prescri. 2013;14:5–7.

    Article  Google Scholar 

  • Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.

    Article  CAS  PubMed  Google Scholar 

  • Everat AB, Boucher JL, Cypress M, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care. 2014;37(supply 1):S120–43.

    Article  Google Scholar 

  • Flower MJ. Diabetes treatment, part 1: diet and exercise. Clin Diab. 2007;25:105–9.

    Article  Google Scholar 

  • Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diab Invest. 2014;4:265–75.

    Article  Google Scholar 

  • Goyal S, Kumar S. Role of glucagon-like peptide-1 in vascular endothelial dysfunction. Indian J Exp Biol. 2010;48:61–9.

    CAS  PubMed  Google Scholar 

  • Guedes EP, Hohl A, de Melo TG, Lauand F. Linagliptin: pharmacology, efficacy and safety in type 2 diabetes treatment. Diabetol Metab Syndr. 2013;5:25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gupta V. Glucagon-like peptide-1 analogues: an overview. Indian J Endocrinol Metab. 2013;17:413–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hollander PA, Kaplan RA, Elbein SC, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care. 1998;21:1288–94.

    Article  CAS  PubMed  Google Scholar 

  • Indian Council of Medical Research. Guidelines for management of type 2 diabetes mellitus. New Delhi: ICMR; 2005.

    Google Scholar 

  • Jain N, Devi K, Dang R, Bhosale U. Nutritional supplements in regulation of diabetes: part I vitamins and antioxidants. APTI Bulletin. 2011a;13(68):14–15.

    Google Scholar 

  • Jain N, Devi K, Dang R, Bhosale U. Nutritional supplements in regulation of diabetes: part II minerals and amino acid. APTI Bulletin. 2011b; 13(69):14–15.

    Google Scholar 

  • Javiya VA, Patel JA. The role of peroxisome proliferator-activated receptor in human disease. Indian J Pharmacol. 2006;38:243–53.

    Article  CAS  Google Scholar 

  • Joshi SR, Parikh RM, Das AK. Insulin – history, biochemistry, physiology and pharmacology. J Assoc Phys India. 2007;55:19–25.

    Google Scholar 

  • Katzung BG, Masters SB, Trevor AJ. Basic and Clinical Pharmacology. New York: Mc-Grew Hill; 2012.

    Google Scholar 

  • Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes: Targets Therapy. 2012;5:313–27.

    CAS  Google Scholar 

  • Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65:385–411.

    Article  CAS  PubMed  Google Scholar 

  • Kumar V, Tripathi MK, Chauhan PK, Singh PK. Different non-pharmacological approaches for management of type 2 diabetes. J Diabetol. 2013;1:1–13.

    Google Scholar 

  • Lambert L. Glucagon-like peptide 1 receptor agonists: a new approach to type 2 diabetes management. S Afr Fam Pract. 2013;55:511–4.

    Article  Google Scholar 

  • London New Drug Groups. APC/DTC Briefing Document. DAPAGLIFLOZIN. Nov 2012. Available from: http://www.medicinesresources.nhs.uk/upload/Dapagliflozin_Nov12.pdf.

  • Majumder A, Chatterjee S. Diabetic dyslipidemia – role of saroglitazar. Med Chem. 2014;4:684–7.

    Article  Google Scholar 

  • Mancini MC, Halpern A. Orlistat in the prevention of diabetes in the obese patient. Vasc Health Risk Manag. 2008;4:325–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Messer C, Green D. A review of pramlintide in the management of diabetes. Clin Med Ther. 2009;1:305–11.

    CAS  Google Scholar 

  • Mkele G. Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes. S Afr Fam Pract. 2013;55:508–10.

    Article  Google Scholar 

  • Nair S, Joseph F, Ewins D, Wilding J, Goenka N. From history to reality: sodium glucose co-transporter 2 inhibitors – a novel therapy for type 2 diabetes mellitus. Pract Diab Int. 2010;27:311–6.

    Article  Google Scholar 

  • Nakano M, Inui A. Metformin and incretin-based therapies up-regulate central and peripheral adenosine monophosphate-activated protein affecting appetite and metabolism. Indian J Endocrinol Metab. 2012;16(supply 3):S529–31.

    Article  PubMed  PubMed Central  Google Scholar 

  • Neumiller JJ. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context. 2014;3:212262.

    PubMed  PubMed Central  Google Scholar 

  • Nolte MS, Karam JH. Pancreatic hormones antidiabetic drugs. In: Katzung BG, editor. Basic & clinical pharmacology. 10th ed. New York: The McGraw-Hill Companies; 2007. p. 683.

    Google Scholar 

  • Olszanecka-Glinianowicz M, Dabrowski P, Kocetak P, et al. Long-term inhibition of intestinal lipase by orlistat improves release of gut hormones increasing satiety in obese women. Pharmacol Rep. 2013;65:666–71.

    Article  CAS  PubMed  Google Scholar 

  • Poole RM, Prossler JE. Tofogliflozin: first global approval. Drugs. 2014;74:939–44.

    Article  CAS  PubMed  Google Scholar 

  • Poole RM, Dungo RT. Ipragliflozin: first global approval. Drugs. 2014;74:611–7.

    Article  CAS  PubMed  Google Scholar 

  • Quianzon CCL, Cheikh IE. History of current non-insulin medications for diabetes mellitus. J Community Hosp Intern Med Perspect. 2012;2:19081.

    Google Scholar 

  • Rajesh R, Naren P, Vidyasagar S, et al. Sodium glucose co transporter 2 (SGLT2) inhibitors: a new sword for the treatment of type 2 diabetes mellitus. Int J Pharma Sci Res. 2010;1:139–47.

    CAS  Google Scholar 

  • Rang HP, Dale MM, Ritter JM, Moore PL. Pharmacology. 5th ed. Edinburgh: Churchill Livingstone; 2003.

    Google Scholar 

  • Reda TK, Geliebter A, Pi-Sunyer FX. Amylin, food intake, and obesity. Obes Res. 2002;10:1087–91.

    Article  CAS  PubMed  Google Scholar 

  • Reddy VS, Sahay RK, Bhadada SK, Agrawa JK, Agrawal NK. Newer oral antidiabetic agents. J Indian Acad Clin Med. 2000;1:246–51.

    Google Scholar 

  • Richard F, Michelle CA, Luigi CX, et al. Lippincott’s illustrated reviews: pharmacology. 4th ed. Baltimore: Lippincott Williams & Wilkins; 2009.

    Google Scholar 

  • Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diab Invest. 2013;4:108–30.

    Article  CAS  Google Scholar 

  • Seshadri KG, Kirubha MHB. Gliptins: a new class of oral antidiabetic agents. Indian J of Pharma Sci. 2009;71:608–14.

    Article  CAS  Google Scholar 

  • Singh MP, Pathak D, Sharma GK, Sharma CS. Peroxisome proliferator-activated receptors (PPARs): a target with a broad therapeutic potential for human diseases: an overview. Pharmacologyonline. 2011;2:58–89.

    CAS  Google Scholar 

  • Stingl H, Schernthaner G. The place of insulin secretagogues in the treatment of type 2 diabetes in the twenty-first century. In: Mogensen CE, editor. Pharmacotherapy of diabetes: new developments. New York: Springer Science; 2007.

    Google Scholar 

  • Tack CJJ, Smits P. Thiazolidinedione derivatives in type 2 diabetes mellitus. Neth J Med. 2006;64:166–74.

    CAS  PubMed  Google Scholar 

  • Tahrani AA, Barnett AH. Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. Diab Ther. 2010;1:45–56.

    Article  CAS  Google Scholar 

  • Thompson A, Kanamarlapudi V. Type 2 diabetes mellitus and glucagon like peptide-1 receptor signaling. Clin Exper Pharmacol. 2013;3:1–18.

    CAS  Google Scholar 

  • Thynne T, Doogue M. Sodium-glucose co-transporter inhibitors. Aust Prescr. 2014;37:14–6.

    Article  Google Scholar 

  • Valentine V. The role of the kidney and sodium-glucose cotransporter-2 inhibition in diabetes management. Clin Diab. 2012;30:151–5.

    Article  Google Scholar 

  • Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med. 2008;25(2):152–6. doi:10.1111/j.1464-5491.2007.02333.x.

    Article  CAS  PubMed  Google Scholar 

  • Viollet B, Guigas B, Garcia NS, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci. 2012;122:253–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yadav S, Prakash A. Insulin therapy. Indian Pediatr. 2006;43:863–72.

    CAS  PubMed  Google Scholar 

  • Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. Clin Invest. 2001;108:1167–74.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Assam Down Town University, Guwahati, Assam, India

    Saikat Sen & Raja Chakraborty

  2. Department of Pharmaceutical Chemistry, Regional Institute of Pharmaceutical Science and Technology, Abhyonagar, Agartala, Tripura, India

    Biplab De

Authors
  1. Saikat Sen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raja Chakraborty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Biplab De
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media Singapore

About this chapter

Cite this chapter

Sen, S., Chakraborty, R., De, B. (2016). Management of Diabetes Mellitus. In: Diabetes Mellitus in 21st Century. Springer, Singapore. https://doi.org/10.1007/978-981-10-1542-7_11

Download citation

Publish with us

Policies and ethics

Search

Navigation